Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Research question</h3><p>To investigate the effects of adropin on hormone levels, glucolipid and amino acid metabolism in patients with polycystic ovary syndrome (PCOS).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Design</h3><p>220 PCOS patients and 67 controls were recruited in the Centre for Reproductive Medicine, Peking University Third Hospital, and their plasma in the basal state were collected for adropin test. Follicular fluids (FF) from 50 PCOS patients and 30 controls undergoing IVF-ET treatments were also collected for adropin analysis.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Plasma and FF adropin levels in PCOS patients were lower than control subjects. Plasma adropin levels were negatively correlated with BMI, FAI, HOMA-IR, levels of androstenedione, fasting insulin and triglyceride, and positive correlated with SHBG and high-density lipoprotein. PCOS patients that were either obese or have glucose intolerance had lower adropin levels. The FF adropin levels were negatively correlated with serum fasting insulin levels and HOMA-IR. A negative correlation was observed between the adropin levels and the levels of isoleucine and valine in the FF of PCOS group. After adjusting for age, BMI, HOMA-IR and HDL, SHBG still significantly impacted the concentration of plasma adropin. After adjusting for age and BMI, the odds of subjects with reduced adropin levels having PCOS still remained significant. The association between plasma adropin and PCOS disappeared following SHBG adjustment.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>The levels of plasma and FF adropin were lower in PCOS patients, which might affect the development of insulin resistance. The association between reduced adropin levels and hyperandrogenemia in PCOS might be mediated through SHBG. The decreased adropin levels are associated with abnormal branch-chain amino acid metabolism in PCOS.</p>

Potential effects of adropin on systemic metabolic and hormonal abnormalities in polycystic ovary syndrome